Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

Matthew Taylor; Scott Antonia; Johanna Bendell; Emiliano Calvo; Dirk J?ger; Filippo de Braud; Patrick A Ott; M Catherine Pietanza; Leora Horn; Dung T Le; Michael A Morse; José A López-Martin; Paolo A Ascierto; Olaf Christensen; Jason S Simon; Chen-Sheng Lin; Joseph Paul Eder

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

【24h】

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

机译：尼伏鲁单抗联合或不联合依普利单抗治疗复发性小细胞肺癌（SCLC）的I / II期研究：CA209-032

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2015年第s2期|共页
作者
Matthew Taylor; Scott Antonia; Johanna Bendell; Emiliano Calvo; Dirk J?ger; Filippo de Braud; Patrick A Ott; M Catherine Pietanza; Leora Horn; Dung T Le; Michael A Morse; José A López-Martin; Paolo A Ascierto; Olaf Christensen; Jason S Simon; Chen-Sheng Lin; Joseph Paul Eder;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-na?ve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [J] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：一项针对nivolumab初治IV期或复发性非小细胞肺癌（NSCLC）患者的nivolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的开放标签随机III期试验（CheckMate 227）
2. MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial [J] . Matthew Hellmann, Scott Antonia, Santiago Ponce, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：单独的MA09.05 Nivolumab或在经常性小细胞肺癌（SCLC）中的IPILIMIMAB：来自Checkmate 032审判的2年存活和更新分析
3. MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial [J] . Matthew Hellmann, Scott Antonia, Santiago Ponce, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：单独的MA09.05 Nivolumab或在经常性小细胞肺癌（SCLC）中的IPILIMIMAB：来自Checkmate 032审判的2年存活和更新分析
4. DEVELOPMENT OF A LIPOSOMAL DRUG CARRIER TO DELIVER SUFFICIENT ANTI-CANCER DRUG INTO MULTI DRUG RESISTANT (MDR)-SMALL CELL LUNG CANCER (SCLC) [C] . T. Kobavashi, Y. Okada, T. Ishida, International symposium on controlled release of bioactive materials;Consumer diversified products conference . 2001

机译：脂质体药物载体的开发，以将有效的抗癌药物输送到抗多药（MDR）-小细胞肺癌（SCLC）中
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 [O] . Matthew Taylor, Scott Antonia, Johanna Bendell, 2015

机译：尼沃单抗联合或不联合依匹莫单抗治疗复发性小细胞肺癌（SCLC）的I / II期研究：CA209-032
7. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 [O] . 2015

机译：尼沃单抗联合或不联合依匹莫单抗治疗复发性小细胞肺癌（SCLC）的I / II期研究：CA209-032

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

著录项

相似文献

相关主题

期刊订阅